Novartis: former AveXis execs impeded investigation into data manipulation

AveXis executives ordered the fudging of numbers at the center of the Zolgensma data integrity scandal and impeded Novartis’ probe into their actions, according to a report submitted by the pharma to FDA and made public Tuesday. To address the agency’s concerns, the pharma plans to integrate AveXis’ quality management process into Novartis’ global network and has committed to timelier notification

Read the full 618 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE